GMAB – Genmab A/S

GMAB — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

1.28

Margin Of Safety %

Put/Call OI Ratio

0.17

EPS Next Q Diff

0.2

EPS Last/This Y

-0.23

EPS This/Next Y

0.56

Price

31.25

Target Price

37.72

Analyst Recom

1.31

Performance Q

Upside

N/A

Beta

0.82

Ticker: GMAB

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-13	GMAB	28.81	0.13	0.05	66891
2026-07-14	GMAB	28.73	0.13	0.28	66945
2026-07-15	GMAB	29.08	0.13	5.50	66923
2026-07-16	GMAB	29	0.13	2.22	66930
2026-07-17	GMAB	28.71	0.13	1.13	66943
2026-07-20	GMAB	27.9	0.12	0.13	62949
2026-07-21	GMAB	28.36	0.12	0.29	62793
2026-07-22	GMAB	28.84	0.13	1.15	62967
2026-07-23	GMAB	29.17	0.13	0.19	63008
2026-07-24	GMAB	28.88	0.13	0.18	63193
2026-07-27	GMAB	28.8	0.13	4.25	63379
2026-07-28	GMAB	28.99	0.13	999.99	63414
2026-07-29	GMAB	28.54	0.13	0.20	63358
2026-07-30	GMAB	28.63	0.13	4.42	63357
2026-07-31	GMAB	28.86	0.13	0.58	63829
2026-08-03	GMAB	28.68	0.13	0.76	63828
2026-08-04	GMAB	29.01	0.13	0.01	63857
2026-08-05	GMAB	29.27	0.13	2.05	63901
2026-08-07	GMAB	31.23	0.17	0.06	66162
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-13	GMAB	28.80	-	7.0	1.05
2026-07-14	GMAB	28.73	-	-13.0	1.05
2026-07-15	GMAB	29.07	-	22.7	1.05
2026-07-16	GMAB	29.00	-	-2.5	1.05
2026-07-17	GMAB	28.70	-	-8.9	1.08
2026-07-20	GMAB	27.91	-	-16.9	1.08
2026-07-21	GMAB	28.36	-	11.2	1.08
2026-07-22	GMAB	28.85	-	26.9	1.08
2026-07-23	GMAB	29.17	-	12.3	1.08
2026-07-24	GMAB	28.87	-	5.9	1.32
2026-07-27	GMAB	28.80	-	16.3	1.32
2026-07-28	GMAB	28.98	-	0.1	1.32
2026-07-29	GMAB	28.52	-	3.1	1.32
2026-07-30	GMAB	28.63	-	29.1	1.32
2026-07-31	GMAB	28.86	-	51.7	1.32
2026-08-03	GMAB	28.68	-	15.8	1.32
2026-08-04	GMAB	28.68	-	15.8	1.32
2026-08-05	GMAB	29.27	-	30.9	1.32
2026-08-06	GMAB	29.86	-	42.2	1.32
2026-08-07	GMAB	31.25	-	82.2	1.32
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-13	GMAB	0.00	-0.21	1.41
2026-07-14	GMAB	0.00	-0.21	1.41
2026-07-15	GMAB	0.00	-0.21	1.41
2026-07-16	GMAB	0.00	-0.21	1.41
2026-07-17	GMAB	0.00	-0.21	1.41
2026-07-20	GMAB	0.00	-0.21	1.41
2026-07-21	GMAB	0.00	-0.21	1.41
2026-07-22	GMAB	0.00	-0.21	1.41
2026-07-23	GMAB	0.00	-0.21	1.41
2026-07-24	GMAB	0.00	-0.21	1.41
2026-07-27	GMAB	0.00	-0.08	1.28
2026-07-28	GMAB	0.00	-0.08	1.28
2026-07-29	GMAB	0.00	-0.08	1.28
2026-07-30	GMAB	0.00	-0.08	1.28
2026-07-31	GMAB	0.00	-0.08	1.28
2026-08-03	GMAB	0.00	-0.09	1.28
2026-08-04	GMAB	0.00	-0.09	1.28
2026-08-05	GMAB	0.00	-0.09	1.28
2026-08-06	GMAB	0.00	-0.09	1.28
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.15

Avg. EPS Est. Current Quarter

0.35

Avg. EPS Est. Next Quarter

0.35

Insider Transactions

Institutional Transactions

-0.09

Beta

0.82

Average Sales Estimate Current Quarter

1076

Average Sales Estimate Next Quarter

7627

Fair Value

31.71

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

36.3

Max Drawdown 5-Year %

-63.1

Target Price

37.72

P/E

22.49

Forward P/E

17.81

PEG

1.01

P/S

4.54

P/B

3.22

P/Free Cash Flow

20.27

EPS

1.33

Average EPS Est. Cur. Y

1.32

EPS Next Y. (Est.)

1.88

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

21.06

Relative Volume

2.62

Return on Equity vs Sector %

-12.9

Return on Equity vs Industry %

3.2

EPS 1 7Days Diff

1.3

EPS 1 30Days Diff

1.32

EBIT Estimation

82.2

No data found for GMAB

GMAB — P/E HistoricalBiotechnology

Genmab A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 3119

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

GMAB

Latest News

—

Caricamento notizie per GMAB…

stock quote shares GMAB – Genmab A/S Stock Price stock today

news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch GMAB – Genmab A/S yahoo finance google finance

stock history GMAB – Genmab A/S invest stock market

stock prices GMAB premarket after hours

ticker GMAB fair value insiders trading

NVO – Novo Nordisk A/S

NVO — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.93

Margin Of Safety %

Put/Call OI Ratio

0.65

EPS Next Q Diff

3.84

EPS Last/This Y

15.87

EPS This/Next Y

1.82

Price

47.24

Target Price

49.1

Analyst Recom

2.38

Performance Q

Upside

N/A

Beta

0.75

Ticker: NVO

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-13	NVO	49.28	0.68	0.85	1358880
2026-07-14	NVO	49.07	0.69	0.57	1368092
2026-07-15	NVO	50.55	0.69	0.25	1378179
2026-07-16	NVO	51.47	0.68	0.47	1399582
2026-07-17	NVO	50.31	0.69	0.94	1420850
2026-07-20	NVO	49.64	0.62	0.38	1252523
2026-07-21	NVO	49.35	0.62	0.66	1274526
2026-07-22	NVO	48.13	0.62	0.55	1286624
2026-07-23	NVO	48.19	0.62	0.61	1298591
2026-07-24	NVO	48.77	0.62	0.65	1307041
2026-07-27	NVO	49.69	0.63	0.53	1286743
2026-07-28	NVO	50.79	0.63	0.40	1300960
2026-07-29	NVO	51.57	0.63	0.76	1315927
2026-07-30	NVO	51.58	0.63	0.72	1338202
2026-07-31	NVO	47.11	0.64	0.54	1369868
2026-08-03	NVO	47.09	0.65	0.53	1346564
2026-08-04	NVO	44.32	0.65	0.73	1387002
2026-08-05	NVO	44.65	0.65	0.46	1477644
2026-08-07	NVO	47.26	0.65	0.36	1507841
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-13	NVO	49.28	-13.1	-4654.1	21.61
2026-07-14	NVO	49.08	-13.1	-4846.3	21.61
2026-07-15	NVO	50.55	-13.1	-4192.4	21.61
2026-07-16	NVO	51.46	-13.1	-4477.9	21.61
2026-07-17	NVO	50.31	-15.7	-5033.2	21.86
2026-07-20	NVO	49.65	-15.7	-4954.6	21.86
2026-07-21	NVO	49.37	-15.7	-5009.4	21.86
2026-07-22	NVO	48.19	-15.7	-4989.6	21.86
2026-07-23	NVO	48.19	-15.7	-4748.9	21.86
2026-07-24	NVO	48.78	-16.4	-4563.6	21.77
2026-07-27	NVO	49.67	-16.4	-4252.3	21.77
2026-07-28	NVO	50.96	-16.4	-4110.5	21.77
2026-07-29	NVO	51.59	-16.4	-4982.6	21.77
2026-07-30	NVO	51.59	-16.4	-5122.0	21.77
2026-07-31	NVO	47.12	-16.4	-6299.5	21.77
2026-08-03	NVO	47.09	-16.4	-5001.2	3.35
2026-08-04	NVO	47.09	-16.4	-5001.2	3.35
2026-08-05	NVO	44.49	-16.4	-4289.9	3.40
2026-08-06	NVO	45.97	-16.4	-3771.8	3.40
2026-08-07	NVO	47.24	4.6	-1075.1	19.43
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-13	NVO	0	-2.79	0.83
2026-07-14	NVO	0	-2.79	0.83
2026-07-15	NVO	0	-2.79	0.83
2026-07-16	NVO	0	-2.79	0.83
2026-07-17	NVO	0	-2.79	0.83
2026-07-20	NVO	0	-2.77	0.83
2026-07-21	NVO	0	-2.77	0.83
2026-07-22	NVO	0	-2.77	0.83
2026-07-23	NVO	0	-2.77	0.83
2026-07-24	NVO	0	-2.77	0.83
2026-07-27	NVO	0	-3.46	0.93
2026-07-28	NVO	0	-3.46	0.93
2026-07-29	NVO	0	-3.46	0.93
2026-07-30	NVO	0	-3.46	0.93
2026-07-31	NVO	0	-3.46	0.93
2026-08-03	NVO	0	-3.35	0.93
2026-08-04	NVO	0	-3.35	0.93
2026-08-05	NVO	0	-3.35	0.93
2026-08-06	NVO	0	-3.35	0.93
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.96

Avg. EPS Est. Current Quarter

4.7

Avg. EPS Est. Next Quarter

4.8

Insider Transactions

Institutional Transactions

-3.35

Beta

0.75

Average Sales Estimate Current Quarter

71946

Average Sales Estimate Next Quarter

75028

Fair Value

48.57

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

68.1

Max Drawdown 5-Year %

-74.7

Target Price

49.1

P/E

11.23

Forward P/E

13.83

PEG

P/S

P/B

P/Free Cash Flow

13.09

EPS

4.09

Average EPS Est. Cur. Y

19.43

EPS Next Y. (Est.)

21.25

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

35.36

Relative Volume

0.98

Return on Equity vs Sector %

25.3

Return on Equity vs Industry %

15.1

EPS 1 7Days Diff

-2.3

EPS 1 30Days Diff

-2.17

EBIT Estimation

-1075.1

No data found for NVO

NVO — P/E HistoricalDrug Manufacturers - General

Novo Nordisk A/S

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 66700

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

NVO

Latest News

—

Caricamento notizie per NVO…

stock quote shares NVO – Novo Nordisk A/S Stock Price stock today

news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch NVO – Novo Nordisk A/S yahoo finance google finance

stock history NVO – Novo Nordisk A/S invest stock market

stock prices NVO premarket after hours

ticker NVO fair value insiders trading

ASND – Ascendis Pharma A/S

ASND — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

5.04

Margin Of Safety %

-29

Put/Call OI Ratio

0.31

EPS Next Q Diff

EPS Last/This Y

16.07

EPS This/Next Y

-2.45

Price

255.71

Target Price

308.91

Analyst Recom

1.1

Performance Q

Upside

21.5%

Beta

0.34

Ticker: ASND

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-13	ASND	265.09	0.29	0.57	14113
2026-07-14	ASND	265.42	0.30	0.02	14242
2026-07-15	ASND	268.3	0.30	0.13	14319
2026-07-16	ASND	259.76	0.29	0.14	14587
2026-07-17	ASND	261	0.29	0.22	14746
2026-07-20	ASND	251.84	0.29	0.54	10909
2026-07-21	ASND	254.92	0.29	0.96	11003
2026-07-22	ASND	251.62	0.29	2.55	11083
2026-07-23	ASND	252.64	0.30	0.09	11112
2026-07-24	ASND	253.8	0.29	0.07	11254
2026-07-27	ASND	253.2	0.29	1.54	11270
2026-07-28	ASND	254.21	0.30	0.51	11408
2026-07-29	ASND	252.21	0.30	0.96	11563
2026-07-30	ASND	250.06	0.31	1.73	11600
2026-07-31	ASND	243.89	0.30	1.58	11643
2026-08-03	ASND	243.24	0.31	1.45	11712
2026-08-04	ASND	244.59	0.31	0.65	11729
2026-08-05	ASND	244.17	0.31	0.06	11744
2026-08-06	ASND	250.11	0.31	1.14	11788
2026-08-07	ASND	255.48	0.31	0.01	11803
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-13	ASND	265.01	-	-	11.46
2026-07-14	ASND	265.49	-	-	11.25
2026-07-15	ASND	268.52	-	-	11.25
2026-07-16	ASND	259.90	-	-	11.25
2026-07-17	ASND	261.06	-	-	11.25
2026-07-20	ASND	251.74	-	-	11.25
2026-07-21	ASND	255.02	-	-	10.54
2026-07-22	ASND	252.20	-	-	10.54
2026-07-23	ASND	252.46	-	-	10.54
2026-07-24	ASND	253.85	-	-	12.22
2026-07-27	ASND	253.37	-	-	12.22
2026-07-28	ASND	254.15	-	-	11.73
2026-07-29	ASND	252.22	-	-	11.73
2026-07-30	ASND	251.15	-	-	11.73
2026-07-31	ASND	243.84	-	-	11.73
2026-08-03	ASND	243.46	-	-	11.73
2026-08-04	ASND	243.46	-	-	11.73
2026-08-05	ASND	244.19	-	-	11.73
2026-08-06	ASND	249.84	-	-	11.73
2026-08-07	ASND	255.71	-	-	11.73
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-13	ASND	-3.19	-41.64	5.32
2026-07-14	ASND	-3.19	-41.64	5.32
2026-07-15	ASND	-3.19	-41.64	5.32
2026-07-16	ASND	-3.19	-41.64	5.32
2026-07-17	ASND	-3.19	-41.64	5.32
2026-07-20	ASND	-3.19	-41.48	5.32
2026-07-21	ASND	-3.19	-41.48	5.32
2026-07-22	ASND	-3.19	-41.48	5.32
2026-07-23	ASND	-3.19	-41.48	5.32
2026-07-24	ASND	-3.19	-41.48	5.32
2026-07-27	ASND	-3.19	-38.97	5.04
2026-07-28	ASND	-3.19	-38.97	5.04
2026-07-29	ASND	-3.19	-38.97	5.04
2026-07-30	ASND	-3.19	-38.97	5.04
2026-07-31	ASND	-3.19	-38.97	5.04
2026-08-03	ASND	-3.19	-38.24	5.04
2026-08-04	ASND	-3.19	-38.24	5.04
2026-08-06	ASND	-3.19	-38.24	5.04
2026-08-07	ASND	-3.19	-38.24	5.04
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.77

Avg. EPS Est. Next Quarter

1.32

Insider Transactions

-3.19

Institutional Transactions

-38.24

Beta

0.34

Average Sales Estimate Current Quarter

331

Average Sales Estimate Next Quarter

355

Fair Value

181.32

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

9.4

Max Drawdown 5-Year %

Target Price

308.91

P/E

28.78

Forward P/E

21.64

PEG

P/S

15.78

P/B

28.22

P/Free Cash Flow

313.69

EPS

8.87

Average EPS Est. Cur. Y

11.73

EPS Next Y. (Est.)

9.29

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

57.88

Relative Volume

0.47

Return on Equity vs Sector %

74.3

Return on Equity vs Industry %

90.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.29

EBIT Estimation

◆ ASND Healthcare

$255.41

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

13/25

Volume

11/15

Valuation

12/20

TP/AR

2/10

Options

6/10

RSI

54.3

Range 1M

37.5%

Sup Dist

4.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

19/30

Estimates

3/20

Inst/Vol

0/15

Options

9/10

EPS Yr

469.1%

52W%

75.1%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +9.1% upside

Quality

27/30

Valuation

2/30

Growth

12/25

Stability

3/10

LT Trend

3/5

Upside

+9.1%

Quality

MoS

-29%

ASND — P/E HistoricalBiotechnology

Ascendis Pharma A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 1189

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

ASND

Latest News

—

Caricamento notizie per ASND…

stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today

news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance

stock history ASND – Ascendis Pharma A/S invest stock market

stock prices ASND premarket after hours

ticker ASND fair value insiders trading

GMAB – Genmab A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: GMAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

NVO – Novo Nordisk A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: NVO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y